US EditionAstraZeneca's big bet on Asia: $10B in deals amid controversy
Summary by Labiotech.eu
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AstraZeneca's big bet on Asia: $10B in deals amid controversy
AstraZeneca has vowed to spend over $10 billion in Asia, particularly in China, to build Beijing into an R&D hub amid probe into fraud scandals. The post AstraZeneca bets on Asia: a surge of deals in March amid fraud probe appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
